Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Cash from Financing Activities (2016 - 2025)

Dare Bioscience (DARE) has disclosed Cash from Financing Activities for 11 consecutive years, with $18.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities rose 4173.22% year-over-year to $18.7 million, compared with a TTM value of $18.7 million through Sep 2025, up 218.65%, and an annual FY2024 reading of $433830.0, down 97.23% over the prior year.
  • Cash from Financing Activities was $18.7 million for Q3 2025 at Dare Bioscience, up from -$43794.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $35.2 million in Q3 2021 and bottomed at -$132012.0 in Q4 2024.
  • Average Cash from Financing Activities over 5 years is $6.2 million, with a median of $875785.0 recorded in 2023.
  • The sharpest move saw Cash from Financing Activities surged 530926900.0% in 2023, then tumbled 137.96% in 2025.
  • Year by year, Cash from Financing Activities stood at $16.0 million in 2021, then crashed by 100.0% to -$1.0 in 2022, then soared by 530926900.0% to $5.3 million in 2023, then plummeted by 102.49% to -$132012.0 in 2024, then soared by 14227.68% to $18.7 million in 2025.
  • Business Quant data shows Cash from Financing Activities for DARE at $18.7 million in Q3 2025, -$43794.0 in Q2 2025, and $246577.0 in Q1 2025.